“It really is frightening for our clients,” CVS Health Senior Vice President of Pharmacy Benefit Management and Specialty Product Development Lucille Accetta said at the Asembia Specialty Pharmacy Summit in Las Vegas, according to Forbes. “We have to be the best purchaser for our clients.”
Speciality drugs derived from biotechnology may account for 1 or 2 percent of the claims health plans process for a client, but they are becoming a more significant part of what they have to administer and manage, according to the report.
Rina Shah, PharmD, Walgreens’ vice president of pharmacy operations and services, said health plans and pharmacies are more closely monitoring patients as soon as they are on these drugs to reduce costs of prescriptions while maintaining access to treatments.
OptumRx Senior Vice President and Chief Pharmacy Officer Michael Einodshofer said health plans are working with clients on options to cover specialty drugs as well as the gene therapies that will be increasingly prescribed in the future, according to the report.
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 17–19 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.
